Correlation Between Combigene and Kancera AB

Specify exactly 2 symbols:
Can any of the company-specific risk be diversified away by investing in both Combigene and Kancera AB at the same time? Although using a correlation coefficient on its own may not help to predict future stock returns, this module helps to understand the diversifiable risk of combining Combigene and Kancera AB into the same portfolio, which is an essential part of the fundamental portfolio management process.
By analyzing existing cross correlation between Combigene AB and Kancera AB, you can compare the effects of market volatilities on Combigene and Kancera AB and check how they will diversify away market risk if combined in the same portfolio for a given time horizon. You can also utilize pair trading strategies of matching a long position in Combigene with a short position of Kancera AB. Check out your portfolio center. Please also check ongoing floating volatility patterns of Combigene and Kancera AB.

Diversification Opportunities for Combigene and Kancera AB

0.21
  Correlation Coefficient

Modest diversification

The 3 months correlation between Combigene and Kancera is 0.21. Overlapping area represents the amount of risk that can be diversified away by holding Combigene AB and Kancera AB in the same portfolio, assuming nothing else is changed. The correlation between historical prices or returns on Kancera AB and Combigene is a relative statistical measure of the degree to which these equity instruments tend to move together. The correlation coefficient measures the extent to which returns on Combigene AB are associated (or correlated) with Kancera AB. Values of the correlation coefficient range from -1 to +1, where. The correlation of zero (0) is possible when the price movement of Kancera AB has no effect on the direction of Combigene i.e., Combigene and Kancera AB go up and down completely randomly.

Pair Corralation between Combigene and Kancera AB

Assuming the 90 days trading horizon Combigene AB is expected to generate 0.83 times more return on investment than Kancera AB. However, Combigene AB is 1.2 times less risky than Kancera AB. It trades about 0.18 of its potential returns per unit of risk. Kancera AB is currently generating about -0.09 per unit of risk. If you would invest  172.00  in Combigene AB on August 28, 2024 and sell it today you would earn a total of  64.00  from holding Combigene AB or generate 37.21% return on investment over 90 days.
Time Period3 Months [change]
DirectionMoves Together 
StrengthVery Weak
Accuracy100.0%
ValuesDaily Returns

Combigene AB  vs.  Kancera AB

 Performance 
       Timeline  
Combigene AB 

Risk-Adjusted Performance

0 of 100

 
Weak
 
Strong
Very Weak
Over the last 90 days Combigene AB has generated negative risk-adjusted returns adding no value to investors with long positions. In spite of comparatively stable basic indicators, Combigene is not utilizing all of its potentials. The recent stock price uproar, may contribute to short-horizon losses for the private investors.
Kancera AB 

Risk-Adjusted Performance

0 of 100

 
Weak
 
Strong
Very Weak
Over the last 90 days Kancera AB has generated negative risk-adjusted returns adding no value to investors with long positions. In spite of uncertain performance in the last few months, the Stock's basic indicators remain comparatively stable which may send shares a bit higher in December 2024. The newest uproar may also be a sign of mid-term up-swing for the firm private investors.

Combigene and Kancera AB Volatility Contrast

   Predicted Return Density   
       Returns  

Pair Trading with Combigene and Kancera AB

The main advantage of trading using opposite Combigene and Kancera AB positions is that it hedges away some unsystematic risk. Because of two separate transactions, even if Combigene position performs unexpectedly, Kancera AB can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Kancera AB will offset losses from the drop in Kancera AB's long position.
The idea behind Combigene AB and Kancera AB pairs trading is to make the combined position market-neutral, meaning the overall market's direction will not affect its win or loss (or potential downside or upside). This can be achieved by designing a pairs trade with two highly correlated stocks or equities that operate in a similar space or sector, making it possible to obtain profits through simple and relatively low-risk investment.
Check out your portfolio center.
Note that this page's information should be used as a complementary analysis to find the right mix of equity instruments to add to your existing portfolios or create a brand new portfolio. You can also try the Sectors module to list of equity sectors categorizing publicly traded companies based on their primary business activities.

Other Complementary Tools

Companies Directory
Evaluate performance of over 100,000 Stocks, Funds, and ETFs against different fundamentals
Idea Breakdown
Analyze constituents of all Macroaxis ideas. Macroaxis investment ideas are predefined, sector-focused investing themes
Sync Your Broker
Sync your existing holdings, watchlists, positions or portfolios from thousands of online brokerage services, banks, investment account aggregators and robo-advisors.
Crypto Correlations
Use cryptocurrency correlation module to diversify your cryptocurrency portfolio across multiple coins
Theme Ratings
Determine theme ratings based on digital equity recommendations. Macroaxis theme ratings are based on combination of fundamental analysis and risk-adjusted market performance